Redwire Corporation has secured a contract from Aspera Biomedicines to carry out space-based research on a cancer treatment.

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...

Agenus has signed $141m partnership agreements with Zydus Lifesciences and its subsidiaries to enhance clinical developments ...

The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).

In this issue: assessing the regulators' role as AI in clinical trials evolves, the potential for a newborn screening refresh ...

Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance ...

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

First-in-human data for the trispecific antibody “suggest a paradigm shift” for the relapsed/refractory multiple myeloma ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

The FDA set a PDUFA date in late 2025 as ziftomenib led to significant disease response in patients with common subtype of ...

SpyGlass Pharma has closed a Series D funding round, raising $75m to advance the company's drug delivery platform.

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...